Nathalie Auger

Institut Gustave Roussy — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index5.3kcitations157works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(37), Lung Cancer Treatments and Mutations(29), Acute Myeloid Leukemia Research(28), PARP inhibition in cancer therapy(19), Chronic Lymphocytic Leukemia Research(13)

Publications157 total

Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025Open Access
RNA-seq Splicing Profile of the CDH1 Gene and Its Impact on the Clinical Pathogenicity Classification of CDH1 Variants: A Description of Alternative and Pathogenic Splicing Patterns
Cancers·2025Open Access
Therapy related myeloid neoplasm, same but different?
Bulletin du Cancer·2025
Biallelic Germline BRCA1 Frameshift Mutations Associated with Isolated Diminished Ovarian Reserve
International Journal of Molecular Sciences·2024· 2 citedOpen Access
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases
Radiology·2024· 12 cited
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients
npj Precision Oncology·2024· 13 citedOpen Access
1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
Blood·2023Open Access
Cytogenetics in the management of hematologic neoplasms with germline predisposition: guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
Current Research in Translational Medicine·2023
Cytogenetics in the management of clonal chromosomal abnormalities of undetermined significance and persistent polyclonal B-cell lymphocytosis: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
Current Research in Translational Medicine·2023· 1 cited
Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
Current Research in Translational Medicine·2023· 2 cited
Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma.
Journal of Clinical Oncology·2023· 1 cited
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2023Open Access
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Jean‐Charles Soria(13), Ludovic Lacroix(9), Benjamin Besse(9), Yohann Loriot(8), Philippe Vielh(8), David Planchard(7), Antoine Hollebecque(6), Maud Ngo‐Camus(6), Fabrice André(6), Emma Pailler(6), Françoise Farace(6), Jean‐Baptiste Micol(6), Christophe Massard(5), Anas Gazzah(5), Gilles Vassal(5), Olivier Delattre(5), Marianne Oulhen(5), Véronique Saada(5), Stéphane de Botton(5), Stefan Michiels(4)